The weekly injection is now the first drug treatment option cleared for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA, which refers to breathing interrupted during sleep ...
That opens the door for broader access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss. Demand for the injection has soared over the last year ...
New pill versions of weight loss drugs, lower prices, and patent expirations will all drive GLP-1 demand in 2026 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback